With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

once-daily danuglipron met pharmacokinetic endpoints and showed potential for promising… CMS said April 4 it will not move forward with a Biden-era proposal to allow Medicare coverage of GLP-1 ...

Weight-loss drugs can be life-changing for people who have struggled to lose weight, however, some people who take them experience unpleasant and concerning side effects. In 2024, roughly 5 per ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...

GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications ... got a weekly shot of semaglutide, the drug in Ozempic and Wegovy ...